captured official filings
KIORA PHARMACEUTICALS INC
Automatically organized from the issuer’s official SEC submissions index. This brief is the starting evidence layer for buyer, FA, legal and broker-dealer review—not a legal conclusion or safety rating.
captured official filings
captured official filings
captured official filings
One evidence index instead of a manual filing hunt.
It groups recent reporting, registration/offer, ownership and governance filings, preserves the SEC source link and keeps a reusable chronology in the issuer’s record.
What teams can pay to automate next.
Cross-version text comparison, monitored alerts, change-specific diligence questions, CSV/PDF exports and a shared deal-team brief are the professional workflow built on this public evidence layer.
Public registration text delta
Comparing S-1/A filed 2023-05-12 with S-1/A filed 2023-06-01.
Tracked-term count changes
Counts are navigation signals, not conclusions. Open both official filings to determine materiality.
- shares66 → 75+9
- offering46 → 48+2
Candidate disclosure excerpts
Only sentence-level additions or removals containing tracked diligence terms are shown. These are reading cues, not materiality findings.
- All share and warrant numbers included in this prospectus are based upon an assumed combined public offering price per share of common stock, Class C Warrant and Class D Warrant of $2.13, the closing price of our common stock on The Nasdaq Capital Market on May 30, 2023.
- The Class C Warrants, Class D Warrants and any shares of Series F Preferred Stock that we issue are not and will not be listed for trading on The Nasdaq Capital Market.
- We have granted a 45-day option to the underwriters to purchase up to an additional 387,324 shares of common stock, Class C Warrants to purchase up to an additional 387,324 shares of common stock and/or Class D Warrants to purchase an additional 387,324 shares of common stock at the public offering price, less the underwriti
- All share numbers included in this prospectus are based upon an assumed combined public offering price per share of common stock and warrant of $2.54, the closing price of our common stock on The Nasdaq Capital Market on May 11, 2023.
- The warrants and any shares of Series F Preferred Stock that we issue are not and will not be listed for trading on The Nasdaq Capital Market.
- We have granted a 45-day option to the underwriters to purchase up to an additional 885,827 shares of common stock and/or warrants to purchase an additional 442,913 shares of common stock at the public offering price, less the underwriting discounts payable by us, to cover over-allotments, if any.
Method: readable plain text is extracted from two official SEC HTML filings, then compared at sentence and tracked-term level. Formatting, exhibit differences and boilerplate may create false positives. This radar is not legal advice, a disclosure completeness opinion or a transaction recommendation.
Save a project-ready issuer record.
US$29 one time. No subscription and no account. You receive the current printable Evidence Snapshot in this browser immediately after verified payment.
- Source-linked filing chronology and registration path
- Machine-detected amendment and tracked-term change view
- Official-source index for project-file archiving and downloadable CSV export
Secure checkout by PayPal.
Save this source-linked record
Download a printable HTML snapshot of the current public-record timeline and change view. A one-time download unlocks a saveable issuer record. Official sources remain controlling.
Captured filing chronology
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 424B3Registration & offeringOpen SEC filing →
- EFFECTRegistration & offeringOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- DEF 14AGovernanceOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-KReporting & material eventsOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- EFFECTRegistration & offeringOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- DEF 14AGovernanceOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-KReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- SC 13G/AOwnershipOpen SEC filing →
- SC 13GOwnershipOpen SEC filing →
- SC 13GOwnershipOpen SEC filing →
- SC 13G/AOwnershipOpen SEC filing →
- SC 13GOwnershipOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 10-QReporting & material eventsOpen SEC filing →
- 8-KReporting & material eventsOpen SEC filing →
- 4OwnershipOpen SEC filing →
- 4OwnershipOpen SEC filing →
Only official SEC submission-index facts are automated here. The brief does not determine shell status, beneficial ownership, capitalization, legal compliance, valuation, active-trading status or transaction suitability. Those questions require the appropriate source documents and independently retained professionals.